Category: EDAP TMS SASyndicate content

EDAP’s losses widen, sales increase in 2012

June 3, 2013 by Sony Salzman

EDAP posts an increase in sales and deepening losses in its fiscal 2012 report.

Edap TMS

EDAP (NSDQ:EDAP) posted a slight bump in sales but a dramatic increase in losses for the fiscal year of 2012

The French device maker posted year-end losses of $9.7 million, or 55¢ per diluted share, on sales of $33.7 million. That compares with 2011 losses of $1.3 million, or 10¢ per diluted share, on sales of $31.2 million.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

FDA accepts Edap's Ablatherm PMA application

April 10, 2013 by Sony Salzman

The FDA accepts Edap SA's pre-market approval application for its Ablatherm prostate cancer treatment, as 2012 losses soar for the French medical device company.

Edap TMS

Edap (NSDQ:EDAP) said the FDA accepted its pre-market approval application for its Ablatherm ultrasound prostate cancer treatment, backed by data from its Enlight investigational device exemption study.

The Vaulx-en-Velin, France-based medical device company also reported that its losses increased by a whopping 646% during the 2012, on an 8% sales increase.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Edap TMS asks FDA to OK Ablatherm prostate treatment

February 1, 2013 by MassDevice staff

French medical device company Edap TMS asks the FDA for pre-market approval of its Ablatherm treatment for prostate cancer.

Edap TMS

EDAP (NSDQ:EDAP) said it filed for pre-market approval of its Ablatherm-HIFU prostate cancer treatment from the FDA.

Globus Medical files for IPO | Wall Street Beat

March 29, 2012 by MassDevice staff

Orthopedic device maker Globus Medical files for an initial public offering that could raise up to $100 million; also, Vocera soars after IPO; Sectra, PenRad ink deal; Misonix, B. Braun in Ecuadoran distribution pact; S&P maintains watch negative on Abbott; outlook on Baxter is stable, according to S&P; plus, a Funding Roundup and analysts' ups and downs.

MassDevice.com Wall Street Beat

Globus Medical filed for an initial public offering yesterday, saying it's planning a reverse split of its existing stock just before the IPO launches.

The Audubon, Pa.-based orthopedic device maker, which ran afoul of the FDA last month, said it hopes to trade under the "GMED" ticker on the New York Stock Exchange.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Device tax spurs Hill-Rom to lay off 200 | Wall Street Beat

March 28, 2012 by MassDevice staff

Hill-Rom Holdings says it plans to lay off 200 workers, or 3% of its workforce, in part due to the looming medical device tax; also, AngioDynamics drops $5M on Microsulis; Kips Bay switches NASDAQ markets; Luna Innovations, Intuitive Surgical extend pact; Asahi Kasei begins $2B bid for Zoll; CRO Cetero files for bankruptcy after FDA probe; NASDAQ warns NeuroMetrix; the 6 players that dominate the EMR market; Intuitive Surgical, GE, Hitachi, Philips win federal contracts; plus a Funding Roundup and analysts' ups and downs.

MassDevice.com Wall Street Beat

Hill-Rom Holdings (NYSE:HRC) said it will lay off about 3% of its workforce, or roughly 200 workers, as it maneuvers to confront the medical device tax set to go into effect next year.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Ortho market growth stable but low | Wall Street Beat

February 15, 2012 by MassDevice staff

Growth rates for the hip and knee implant market are stable but in the low-single-digit range, according to analysts who attended the American Academy of Orthopedic Surgeons last week; also, Baxter, Hill-Rom close buyouts; BioStart closes down; Medisafe 1 to launch share buyback; Solos Endoscopy retires 150m shares; Daxor backtracks, will register as investment company; and analysts' ups and downs, a deals roundup and a funding roundup.

MassDevice.com Wall Street Beat

The market for hip and knee implants is stable but mired in a low-growth stage, according to analysts who attended the American Academy of Orthopedic Surgeons conference in San Francisco last week.

Although the abrupt departure of Stryker CEO Steve MacMillan drew the lion's share of attention at the AAOS event, analysts from Barclays Capital and Leerink Swann agreed that the sector's outlook calls for low-single-digit growth.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp